Syphilis Immunoassay Diagnostics Market Outlook 2032
The global syphilis immunoassay diagnostics market size was USD 32.1 Billion in 2023 and is projected to reach USD 58.5 Billion by 2032, expanding at a CAGR of 6.9% during 2024–2032. The market growth is attributed to the increasing demand for rapid and accurate diagnostic solutions across the globe.
Increasing awareness of sexually transmitted infections (STIs) is resulting in a high utilization of rapid and accurate diagnostic solutions, including syphilis immunoassay diagnostics. Public health campaigns and initiatives aimed at educating individuals about the risks of syphilis transmission contribute to the high demand for syphilis immunoassay diagnostics solutions. Furthermore, the increasing incidence of chlamydia further propels the use of immunoassay diagnostics which further boosts the market during the forecast period.
-
As per the report published by the Centers for Disease Control and Prevention on January 30, 2024, the rate of reported chlamydia cases among men by increased 1.8% (from 357.4 to 363.7 per 100,000) from 2021 to 2022. However, the rate of reported cases among women decreased by 1.2% (from 628.8 to 621.2 per 100,000) during the same period.
Syphilis Immunoassay Diagnostics Market Dynamics
Major Drivers
Increasing prevalence of syphilis infections globally is expected to drive the market during the forecast period. Immunoassay diagnostics methods are widely used for management of syphilis infections, particularly in high-risk populations and various healthcare settings. Moreover, the growing emphasis on early detection and treatment further boosts the demand for advanced syphilis immunoassay diagnostics for timely diagnosis.
-
According to a report from the Centers for Disease Control and Prevention, over 2.5 million cases of syphilis, gonorrhea, and chlamydia were reported in the US in 2022.
Existing Restraints
High cost associated with syphilis immunoassay diagnostics solutions is expected to hinder the market in the coming years. The expenses related to the development, production, and distribution of diagnostic kits reduce the adoption of these diagnostic methods, particularly in low-income regions where healthcare budgets are limited. Moreover, the limited sensitivity and specificity of some syphilis immunoassay diagnostics further hamper the market.
Emerging Opportunities
Continuous advancements in immunoassay technologies are expected to create immense opportunities for the players competing in the market. Manufacturers are aiming to develop accurate and reliable diagnostic tests to enhance workflow efficiency of testing processes. Moreover, the development of multiplex assays and automated testing platforms are further boosting the demand for innovative syphilis diagnostics solutions.
Scope of the Syphilis Immunoassay Diagnostics Market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Syphilis Immunoassay Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2023
|
|
Historic Data
|
2017 -2022
|
|
Forecast Period
|
2024–2032
|
|
Segmentation
|
Product (Reagents, Analyzers, Kits, and Others), Technology (Enzyme-linked Immunosorbent Assay and Chemiluminescence Immunoassay), and End-user (Diagnostics Labs, Blood Banks, Hospitals, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Abbott; BD; Beckman Coulter; BIOMÉRIEUX; BioRad Laboratories, Inc; Danaher Corporation; DiaSorin S.p.A; F. Hoffmann-La Roche Ltd; Fujirebio; and Siemens Healthineers AG.
|
Syphilis Immunoassay Diagnostics Market Segment Insights
Product Segment Analysis
Based on product, the syphilis immunoassay diagnostics market is divided into reagents, analyzers, kits, and others. The kits segment held the major share of the market in 2023, due to their convenience and rapid results which make them suitable for point-of-care testing. Additionally, the growing preference for self-testing kits among individuals seeking discreet and convenient testing options contributed to the segment growth.
The analyzer segment is expected to expand at a significant growth rate in the coming years, owing to the increasing demand for centralized testing solutions and advancements in immunoassay analyzer technology enhancing throughput and efficiency. Additionally, the growing trend toward laboratory consolidation and automation in healthcare institutions is anticipated to fuel the adoption of advanced analyzers for syphilis diagnostics.
Technology Segment Analysis
On the basis of technology, the global market is segregated into enzyme-linked immunosorbent assay and chemiluminescence immunoassay. The enzyme-linked immunosorbent assay (ELISA) segment held a large market share in 2023, due to its widespread adoption in clinical laboratories and healthcare facilities. They offer proven performance, established protocols, and availability of commercially available kits. Additionally, the cost-effectiveness of ELISA technology as compared to alternative diagnostic methods is boosting its demand.
The chemiluminescence immunoassay (CLIA) segment is anticipated to expand at a substantial CAGR during the forecast period, owing to its growing utilization of chemiluminescent reactions to detect syphilis-specific antibodies in patient samples. CLIA offers enhanced sensitivity and reduced potential for cross-reactivity as compared to traditional ELISA assays. Moreover, the flexibility of ELISA assays to accommodate various sample types and throughput levels further propels the segment during the forecast period.
End-user Segment Analysis
Based on end-user, the syphilis immunoassay diagnostics market is segmented into diagnostics labs, blood banks, hospitals, and others. The diagnostics labs segment is projected to register a robust growth rate during the assessment years, owing to the increasing trend towards outsourcing laboratory services and growing demand for specialized testing expertise for syphilis infections. Additionally, the expansion of diagnostics lab networks, particularly in emerging countries is anticipated to fuel the demand for syphilis immunoassay diagnostics.
Regional Outlook
In terms of region, the global syphilis immunoassay diagnostics market is classified as Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa. North America held a major market share in 2023, due to a high awareness about syphilis and robust healthcare infrastructure. Additionally, proactive government initiatives and public health campaigns aimed at promoting syphilis prevention further propel the market in this region.
-
According to the report published by the Centers for Disease Control and Prevention on January 30, 2024, American Indian or Alaska Native people had the highest rate of congenital syphilis in 2022, with 155 cases per 10,000 live births.
The market in Asia Pacific is projected to grow at a significant pace in the coming years, owing to the rising prevalence rates of sexually transmitted infections (STIs) and expanding healthcare infrastructure. Furthermore, investments in healthcare technology and the adoption of point-of-care testing (POCT) solutions for syphilis detection are likely to fuel the market in the coming years.
Segments
The syphilis immunoassay diagnostics market has been segmented on the basis of
Product
- Reagents
- Analyzers
- Kits
- Others
Technology
- Enzyme-linked Immunosorbent Assay
- Chemiluminescence Immunoassay
End-user
- Diagnostics Labs
- Blood Banks
- Hospitals
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global syphilis immunoassay diagnostics market are Abbott; BD; Beckman Coulter; BIOMÉRIEUX; BioRad Laboratories, Inc; Danaher Corporation; DiaSorin S.p.A; F. Hoffmann-La Roche Ltd; Fujirebio; and Siemens Healthineers AG
These companies use development strategies including mergers, acquisitions, partnerships, collaboration, and product launches to expand their consumer base worldwide.
-
On July 25, 2023, Beckman Coulter, Inc, a key manufacturer of complex biomedical testing, announced the launch of the DxI 9000 Access Immunoassay Analyzer in North America. This analyzer is specifically designed to meet the demands of clinical laboratories in terms of speed, reliability, reproducibility, quality, and menu expansion.
Request For Customization
Enquiry Before Buying
Speak With Analyst
